Androgen Reduction in Congenital Adrenal Hyperplasia
NCT03548246 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL
Last updated 2023-02-01
Summary
Children with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency tend to have elevated circulating levels of androgens, which can accelerate skeletal maturation and adversely impact adult height. Additionally, these children require supraphysiologic doses of hydrocortisone to suppress secretion of adrenal androgen precursors, and this treatment can retard linear growth. This study seeks to use oral abiraterone acetate (Zytiga)as an adjunct to approved CAH therapy (oral hydrocortisone and fludrocortisone) for pre-pubescent children with classic 21-hydroxylase deficiency in order to reduce daily requirement of hydrocortisone.
Conditions
- Congenital Adrenal Hyperplasia
Interventions
- DRUG
-
Abiraterone acetate
Daily oral abiraterone acetate for 2 years. The dose will be specified based on pharmacodynamic data from Phase 1.
- DRUG
-
Daily placebo for 2 years.
- DRUG
-
Hydrocortisone
Hydrocortisone will be administered at a starting dose of 7-9 mg/M2/d and adjusted as necessary based on 17-hydroxyprogesterone and ACTH levels.
- DRUG
-
Fludrocortisone
Fludrocortisone will be administered at the dose the subject was taking a study entry and adjusted as necessary to keep plasma renin in the high normal range.
Sponsors & Collaborators
-
National Institutes of Health Clinical Center (CC)
collaborator NIH - collaborator OTHER
-
Children's Hospital Los Angeles
collaborator OTHER -
Feinstein Institute for Medical Research
collaborator OTHER -
University of Texas Southwestern Medical Center
lead OTHER
Principal Investigators
-
Perrin C White, MD · UT Southwestern Medical Center
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- TRIPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 2 Years
- Max Age
- 9 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-01-31
- Primary Completion
- 2026-01-31
- Completion
- 2026-01-31
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
Growth Hormone and Chromosome 18q- and Abnormal Growth
NCT00134420 ·Status: COMPLETED ·Phase: PHASE3
-
Linear Growth of Children With Congenital Adrenal Hyperplasia
NCT04087148 ·Status: UNKNOWN
-
Study of Weekly ALTU-238 Compared With Daily Nutropin AQ in Prepubertal Children With Growth Hormone Deficiency
NCT00837863 ·Status: UNKNOWN ·Phase: PHASE2
-
Continuous Subcutaneous Hydrocortisone Infusion in Congenital Adrenal Hyperplasia
NCT01771328 ·Status: UNKNOWN ·Phase: PHASE2
-
Aromatase Inhibitors, Alone And In Combination With Growth Hormone In Adolescent Boys With Idiopathic Short Stature
NCT01248416 ·Status: COMPLETED ·Phase: PHASE3
-
Growth Hormone (GH) in Congenital Adrenal Hyperplasia
NCT03162172 ·Status: COMPLETED
-
Research Study for Children With Salt Wasting Congenital Adrenal Hyperplasia
NCT00529841 ·Status: COMPLETED ·Phase: NA
-
Adult Height Prediction in Congenital Adrenal Hyperplasia
NCT03162159 ·Status: COMPLETED
-
Effect of Adrenocorticotropic Hormone on Vascular Endothelial Growth Factor Release in Children Study
NCT03709381 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Phase II Randomized Study of the Effects of Growth Hormone on Children and Adolescents on Maintenance Dialysis
NCT00004340 ·Status: COMPLETED ·Phase: PHASE2
-
Congenital Adrenal Hyperplasia Once Daily Hydrocortisone Treatment
NCT03760835 ·Status: RECRUITING ·Phase: PHASE4
-
Effect of Longer-term Adrenal Suppression Using Low Dose Hydrocortisone on Androgen Overproduction
NCT01422733 ·Status: WITHDRAWN ·Phase: EARLY_PHASE1
-
The Effects of Hormones in Growth Hormone-Treated Girls With Turner Syndrome
NCT00001343 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Luteinizing Hormone-Releasing Hormone Analog (LHRHa) in Pubertal Patients With Extreme Short Stature
NCT00001190 ·Status: COMPLETED ·Phase: PHASE2
-
Arimidex Multicenter Trial in Growth Hormone (GH) Deficient Boys
NCT00133354 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Clinical Trial of Growth Hormone in MPS I, II, and VI
NCT00748969 ·Status: TERMINATED ·Phase: PHASE2/PHASE3
-
Growth Response in Short Children Suffering From a Disease With Growth Retardation and Treated With Somatropin
NCT00488124 ·Status: COMPLETED ·Phase: PHASE2
-
Dexamethasone Treatment of Congenital Adrenal Hyperplasia
NCT00621985 ·Status: COMPLETED ·Phase: PHASE2
-
COrticosteroid in Congenital Adrenal Hyperplasia
NCT02552251 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Does Spironolactone Normalize Sleep-wake Luteinizing Hormone Pulse Frequency in Pubertal Girls With Hyperandrogenism?
NCT04723862 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Growth Hormone Therapy in Osteogenesis Imperfecta
NCT00001305 ·Status: COMPLETED ·Phase: PHASE3
-
Comparison of Two Forms of Hydrocortisone in Patients With Congenital Adrenal Hyperplasia
NCT00519818 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Growth Hormone and GnRH Agonist in Adolescents With Acquired Hypothyroidism
NCT00206375 ·Status: TERMINATED ·Phase: PHASE4
-
A Phase 2, Safety and Dose-Finding Study in Treatment-Naive, Pre-Pubertal, Growth Hormone-Deficient Children
NCT02092077 ·Status: TERMINATED ·Phase: PHASE2
-
Long-Term Growth and Skeletal Effects of Early Growth Hormone Treatment in Turner Syndrome
NCT00266656 ·Status: COMPLETED ·Phase: PHASE4